TTC3

TTC3 is a RING-domain E3 ubiquitin ligase that uses its tetratricopeptide repeats to selectively recognize phosphorylated substrates and direct them for K48-linked ubiquitination and proteasomal degradation, thereby terminating their signaling (PMID:20059950, PMID:20059946). Its prototypical substrate is activated (phospho-)Akt, which TTC3 binds and degrades within the nucleus to shut down Akt signaling (PMID:20059950, PMID:20059946); this recognition is enhanced when KIF18A binds TTC3 and strengthens the TTC3–phospho-Akt interaction (PMID:38372748). Through analogous degradative control of additional substrates—SMURF2, APPL1, and DDX3X—TTC3 tunes multiple signaling axes: it stabilizes SMAD2/3 signaling by degrading SMURF2 and operates in a TGF-β1-driven positive feedback loop to promote epithelial-mesenchymal transition and myofibroblast differentiation (PMID:30696809), suppresses LKB1-AMPKα activation by degrading APPL1 to drive airway remodeling (PMID:41520735), and controls DDX3X levels in a manner antagonized by the competing binder TMEM92 (PMID:42138474). Independently of its ligase activity, TTC3 acts in neurons by binding the RhoA effectors Citron kinase (CIT-K) and Citron-N (CIT-N) to promote actin polymerization, inhibit NGF-induced neurite extension, and regulate Golgi compactness (PMID:17488780, PMID:24695496). Consistent with these dual roles, TTC3 overaccumulates downstream of defective ribosome-associated quality control when the RQC ligase LTN1 is lost, producing dendritic abnormalities, reduced surface GABAA receptors, and cognitive deficits that are partially rescued by TTC3 knockdown (PMID:36917672), and an Alzheimer's-risk variant (p.S1038C) reduces TTC3 expression and perturbs PI3K-Akt signaling and actin-dependent neuronal morphology (PMID:37677864, PMID:37292815).

1. 2007 High

   Established TTC3 as a regulator of neuronal differentiation by identifying its physical partners, addressing what cellular process TTC3 participates in.

   Evidence Reciprocal Co-IP and CIT-K RNAi epistasis with neurite extension assays in PC12 cells

   PMID:17488780

   Open questions at the time

   • Did not define whether ligase activity is required for the CIT-K-dependent effect
   • Molecular link between TTC3 and RhoA upstream not resolved
2. 2009 High

   Defined TTC3's core biochemical activity—answering how it acts at the molecular level—by showing it is an E3 ligase that recognizes phospho-Akt and degrades it to terminate signaling.

   Evidence In vitro ubiquitination assay, Co-IP, nuclear fractionation, and siRNA knockdown with phospho-Akt measurement

   PMID:20059946 PMID:20059950

   Open questions at the time

   • Structural basis of phospho-substrate recognition not determined
   • Generality of phospho-substrate preference beyond Akt unaddressed at the time
3. 2014 Medium

   Resolved the downstream effector pathway of TTC3 in neurons, clarifying how it controls cell shape via cytoskeletal and organelle organization.

   Evidence TTC3 gain/loss-of-function in primary neurons with ROCK inhibition, CIT-N/myosin IIa RNAi, F-actin and Golgi morphology readouts

   PMID:24695496

   Open questions at the time

   • Context-dependent wiring between neurite vs Golgi pathways left mechanistically undefined
   • Single lab
4. 2019 High

   Extended TTC3's substrate repertoire beyond Akt, showing it degrades SMURF2 to amplify TGF-β/SMAD signaling, establishing a role in EMT and fibrosis.

   Evidence In vitro and in-cell ubiquitylation assays, Co-IP, knockdown in epithelial/fibroblast cells, bleomycin mouse model

   PMID:30696809

   Open questions at the time

   • Whether phosphorylation gates SMURF2 recognition unknown
   • Direct test of feedback loop kinetics absent
5. 2018 Medium

   Addressed how TTC3 protein itself is handled, showing proteolytic fragments form cytotoxic nuclear aggregates regulated by the proteasome.

   Evidence Tagged fusion constructs, MG132 treatment, solubility fractionation, viability assays

   PMID:30203323

   Open questions at the time

   • Physiological relevance of fragmentation in vivo not shown
   • Protease responsible for cleavage not identified
6. 2023 High

   Placed TTC3 downstream of ribosome-associated quality control, explaining how its dysregulated accumulation causes neurodevelopmental and cognitive deficits.

   Evidence Ltn1 KO mice, in vivo TTC3 knockdown rescue, dendritic and surface GABAA receptor readouts, behavioral assays

   PMID:36917672

   Open questions at the time

   • Substrate(s) of TTC3 mediating dendritic/receptor phenotype unidentified
   • Whether ligase activity drives the phenotype untested
7. 2023 Medium

   Connected a disease-risk TTC3 variant to neuronal phenotypes, linking reduced TTC3 levels to PI3K-Akt and actin dysregulation in human cortical neurons.

   Evidence CRISPR isogenic iPSC lines, cortical neuron differentiation, transcriptomics, neurite morphometry, actin-targeting pharmacological rescue

   PMID:37292815 PMID:37677864

   Open questions at the time

   • Causal mechanism linking variant to expression change unknown
   • Single lab; in vivo confirmation absent
8. 2024 Medium

   Identified a positive regulator of TTC3 ligase function, showing KIF18A enhances TTC3–phospho-Akt binding to suppress AKT/mTOR in fibrosis.

   Evidence Co-IP of KIF18A–TTC3 and TTC3–p-Akt, KIF18A manipulation, CCl4 liver fibrosis model, ubiquitination assays

   PMID:38372748

   Open questions at the time

   • Mechanism by which KIF18A strengthens the interaction unresolved
   • Single lab
9. 2026 Medium

   Broadened the TTC3 substrate set further (APPL1, DDX3X) and identified a competitive binder, refining how TTC3 modulates LKB1-AMPK signaling and how its degradation of substrates can be blocked.

   Evidence Ubiquitination assays, competitive binding (TMEM92), in vivo OVA and xenograft models, LKB1 nuclear export tracking, RNA-seq

   PMID:41520735 PMID:42138474

   Open questions at the time

   • Whether these substrates share the phospho-recognition logic of Akt unknown
   • Single lab per substrate; reciprocal validation limited
10. 2026 Medium

    Demonstrated an organismal requirement for TTC3, showing knockout causes pulmonary developmental defects and that TTC3 activates PI3K/Akt in fibrosis.

    Evidence Ttc3 KO mice lung phenotype, in vivo siRNA nanoparticle rescue in bleomycin fibrosis, PI3K/Akt readouts, histology

    PMID:41796874

    Open questions at the time

    • Apparent activation of PI3K/Akt contrasts with TTC3-mediated phospho-Akt degradation; reconciliation not provided
    • Tissue-specific substrate dependence undefined

• How TTC3's RING/TPR architecture achieves selective recognition of phosphorylated substrates, and whether its diverse substrates (Akt, SMURF2, APPL1, DDX3X) share a common recognition determinant, remains unresolved.
• No structural model of substrate recognition
• Determinants distinguishing degradative substrates from non-catalytic CIT-K/CIT-N partners undefined